In a patient with acute kidney injury who is taking empagliflozin (Jardiance) 25 mg daily, perindopril 8 mg daily, amitriptyline 10 mg daily, and pregabalin 300 mg twice daily, which medications should be dose‑adjusted or discontinued?

Medication Adjustments in Acute Kidney Injury

In this patient with AKI, you should immediately hold or reduce perindopril and pregabalin, while carefully monitoring Jardiance and amitriptyline based on AKI severity and volume status.

Perindopril (ACE Inhibitor) - HOLD or REDUCE

Perindopril requires immediate dose adjustment or temporary discontinuation 1. ACE inhibitors can worsen AKI through hemodynamic effects—they reduce filtration fraction and can cause or exacerbate kidney injury, particularly when patients are volume depleted or have compromised renal perfusion 1.

• Action: Hold temporarily if the patient is hemodynamically unstable, volume depleted, or has significant AKI (Stage 2-3)
• Rationale: The risk-benefit ratio shifts unfavorably during AKI episodes. While ACE inhibitors provide long-term cardiovascular and renal protection in stable CKD, these benefits are not proven during acute kidney disease 1
• Restart timing: Resume only when GFR has stabilized and volume status is optimized 1
• Dosing if continued: According to FDA labeling, for creatinine clearance >30 mL/min, initial dose should be 2 mg/day with maximum 8 mg/day 2. For CrCl <30 mL/min, safety and efficacy are not established 2

Critical caveat: Two studies showed increased 30-day mortality when ACE inhibitors were not restarted post-operatively, possibly from hypertensive rebound causing cardiac decompensation 1. This underscores the importance of timely reinitiation once stable.

Pregabalin - REDUCE DOSE

Pregabalin requires mandatory dose reduction as it is renally eliminated and accumulates significantly in renal impairment 3. The current dose of 300 mg BID (600 mg/day total) is excessive for someone with AKI.

• Action: Reduce dose immediately based on estimated GFR/creatinine clearance
• Rationale: Pregabalin undergoes minimal hepatic metabolism and is primarily excreted unchanged in urine. Accumulation leads to increased CNS toxicity (sedation, confusion, dizziness) 3
• Monitoring: Watch for excessive sedation, confusion, or ataxia indicating drug accumulation

Jardiance (Empagliflozin) - HOLD TEMPORARILY

Jardiance should be held during the acute phase of AKI 4. While SGLT-2 inhibitors like empagliflozin have demonstrated renal protective effects in chronic kidney disease and recent data suggests they may not increase AKI risk 5, their use during active AKI is problematic.

• Action: Hold temporarily during acute AKI episode
• Rationale: SGLT-2 inhibitors cause osmotic diuresis and can worsen volume depletion, potentially exacerbating hemodynamically-mediated AKI. The drug's efficacy is also reduced when GFR is significantly impaired 4
• Restart timing: Can be restarted once kidney function stabilizes and volume status is adequate
• Evidence nuance: Recent Korean data showed dapagliflozin was associated with 34% lower AKI risk compared to sitagliptin (HR 0.66) 5, and empagliflozin is being studied in various kidney diseases 6. However, these findings apply to chronic use for prevention, not during active AKI

Amitriptyline - MONITOR CLOSELY, Consider Dose Reduction

Amitriptyline at 10 mg daily is a relatively low dose but still requires caution 3.

• Action: Continue with close monitoring; consider dose reduction if AKI is severe (Stage 3) or prolonged
• Rationale: Amitriptyline undergoes hepatic metabolism, but AKI can affect hepatic drug metabolism through organ crosstalk 1. At this low dose (10 mg), the risk is lower than with higher doses
• Monitoring: Watch for anticholinergic effects, sedation, and cardiac conduction abnormalities
• Precaution: Amitriptyline has been used in renal failure but requires specific precautions and dose reduction 3

Key Management Principles

Nephrotoxin management during AKI requires systematic evaluation 1:

1. Assess causality: Determine if any medication is the potential cause of AKI
2. Evaluate essentiality: Non-essential nephrotoxic drugs should be discontinued
3. Consider alternatives: Use less nephrotoxic alternatives when available
4. Monitor function: Regular creatinine and volume status monitoring while on any potentially problematic medication

Common pitfall: Failing to restart ACE inhibitors after AKI resolution can lead to worse cardiovascular outcomes 1. Plan for systematic medication review and reinitiation as kidney function recovers.

Volume status is critical: Ensure adequate hydration before restarting Jardiance or continuing perindopril, as both can worsen outcomes in volume-depleted states 1.